.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Chinese Patent Office
Covington
Cipla
US Army
McKesson
Queensland Health
Fish and Richardson
Daiichi Sankyo
Citi

Generated: November 19, 2017

DrugPatentWatch Database Preview

MAXALT Drug Profile

« Back to Dashboard

Which patents cover Maxalt, and what generic Maxalt alternatives are available?

Maxalt is a drug marketed by Merck and is included in two NDAs.

The generic ingredient in MAXALT is rizatriptan benzoate. There are twenty-two drug master file entries for this compound. Thirty suppliers are listed for this compound. Additional details are available on the rizatriptan benzoate profile page.

Summary for MAXALT

US Patents:0
Applicants:1
NDAs:2
Suppliers / Packagers: 4
Clinical Trials: 6
Drug Prices:see details
DailyMed Link:MAXALT at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Merck
MAXALT
rizatriptan benzoate
TABLET;ORAL020864-001Jun 29, 1998ABRXYesNo► Subscribe► Subscribe► Subscribe
Merck
MAXALT-MLT
rizatriptan benzoate
TABLET, ORALLY DISINTEGRATING;ORAL020865-002Jun 29, 1998ABRXYesYes► Subscribe► Subscribe► Subscribe
Merck
MAXALT
rizatriptan benzoate
TABLET;ORAL020864-002Jun 29, 1998ABRXYesYes► Subscribe► Subscribe► Subscribe
Merck
MAXALT-MLT
rizatriptan benzoate
TABLET, ORALLY DISINTEGRATING;ORAL020865-001Jun 29, 1998ABRXYesNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: MAXALT

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Merck
MAXALT
rizatriptan benzoate
TABLET;ORAL020864-001Jun 29, 1998► Subscribe► Subscribe
Merck
MAXALT
rizatriptan benzoate
TABLET;ORAL020864-002Jun 29, 1998► Subscribe► Subscribe
Merck
MAXALT
rizatriptan benzoate
TABLET;ORAL020864-002Jun 29, 1998► Subscribe► Subscribe
Merck
MAXALT
rizatriptan benzoate
TABLET;ORAL020864-001Jun 29, 1998► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for MAXALT

Drugname Dosage Strength RLD Submissiondate
rizatriptan benzoateOrally Disintegrating Tablets5 mg and 10 mgMaxalt-MLT2/17/2006
rizatriptan benzoateTablets5 mg and 10 mgMaxalt9/2/2004
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Queensland Health
Chubb
Merck
Deloitte
Cipla
AstraZeneca
Chinese Patent Office
Express Scripts
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot